LNDC Landec Corp.

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at four upcoming industry events. Details of the company’s activities at these events are as follows:

  • Medical Aesthetic Injectable Summit 2024

    Conference Date/Location: October 4-5, 2024, in Marbella, Spain

    Details: Darren Hieber, Lifecore’s senior vice president of corporate development and partnerships, will participate in a roundtable discussion and the company will host meetings with existing and prospective customers and partners

    Roundtable Topic: Filler Raw Materials

    Roundtable Timing: 3:20 – 3:40 p.m. local time
  • CPHI Worldwide 2024

    Conference Date/Location: October 8-10, 2024, in Milan, Italy

    Details: Lifecore will have a significant business development and marketing presence, including hosting booth meetings with existing and prospective customers and partners.
  • 21st Annual Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

    Conference Date/Location: October 22-23, 2024, in Phoenix, AZ

    Details: Lifecore will have a significant business development and marketing presence, including hosting booth meetings with existing and prospective customers and partners
  • 14th Annual Partnership Opportunities in Drug Delivery Conference

    Conference Date/Location: October 28-29, 2024, in Boston, MA

    Details: Ryan Swanson, Ph.D., Lifecore’s director of process development, will deliver a presentation as part of the event’s injectable formulations and technologies track, and the company will host booth meetings with existing and prospective customers and partners.

    Presentation Title: Avoid Injectables Pitfalls: Five Early Considerations to Shorten Timelines and Reduce Costs Throughout Your Program

    Presentation Timing: 5:15 – 5:30 p.m. Eastern on Monday, October 28

For booth information and links to event websites, consult

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: ) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at .



Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
 

Tim Brons (Media)
415-675-7402
 
EN
25/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovat...

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clini...

 PRESS RELEASE

Lifecore Biomedical to Participate at DCAT Week 2026

Lifecore Biomedical to Participate at DCAT Week 2026 CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City. Details regarding Lifecore’s participation are as follows: DCAT Week 2026Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and n...

 PRESS RELEASE

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to tw...

 PRESS RELEASE

Lifecore Biomedical to be Added to Nasdaq Biotech Index

Lifecore Biomedical to be Added to Nasdaq Biotech Index CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. The Nasdaq Biotechnology Index ...

 PRESS RELEASE

Lifecore Biomedical Signs CDMO Master Services Agreement with New Larg...

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer  Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement wit...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch